Pfizer (PFE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 28, 2026
- EPS actual
- $0.77
- EPS estimate
- $0.68
- EPS surprise
- +12.87%
- Revenue surprise
- +4.41%
- Revenue
- $15.0B
- Revenue estimate
- $14.4B
- Reported
- Aug 4, 2026
Pfizer reported Q2 2026 results on August 4, 2026. Earnings per share came in at $0.77, ahead of the $0.68 estimate by 12.87%. Revenue was $15.0 billion, above the $14.4 billion consensus. Compared with Q2 2025, EPS slipped about 1% from $0.78, while revenue rose about 2% from $14.7 billion.
The longer record shows a sharp reset after 2022. That year, Pfizer earned $6.58 per share on $100.3 billion in revenue. Annual EPS fell to $1.83 in 2023 as revenue dropped to $58.4 billion. Q3 2023 was a loss of $0.17 per share, the only loss in the table and the only quarter that missed its estimate. Annual EPS then recovered to $3.11 in 2024 and $3.23 in 2025. The first half of 2026 adds up to $1.52, about 11% less than the same period a year earlier. Over the last 20 quarters, Pfizer beat the EPS estimate 19 times, often by wide margins.
Pfizer reported Q3 between October 29 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue holds near $15 billion.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.68 | $0.77 | +12.87% | $15.0B | SEC |
| Q1 2026 | May 5, 2026 | $0.72 | $0.75 | +3.92% | $14.5B | SEC |
| Q4 2025 | Feb 3, 2026 | $0.57 | $0.66 | +16.42% | $17.6B | SEC |
| Q3 2025 | Nov 4, 2025 | $0.63 | $0.87 | +37.53% | $16.7B | SEC |
| Q2 2025 | Aug 5, 2025 | $0.58 | $0.78 | +34.39% | $14.7B | SEC |
| Q1 2025 | Apr 29, 2025 | $0.67 | $0.92 | +38.22% | $13.7B | SEC |
| Q4 2024 | Feb 4, 2025 | $0.47 | $0.63 | +33.59% | $17.8B | SEC |
| Q3 2024 | Oct 29, 2024 | $0.61 | $1.06 | +72.53% | $17.7B | SEC |
| Q2 2024 | Jul 30, 2024 | $0.46 | $0.60 | +31.03% | $13.3B | SEC |
| Q1 2024 | May 1, 2024 | $0.52 | $0.82 | +58.98% | $14.9B | SEC |
| Q4 2023 | Jan 30, 2024 | −$0.16 | $0.10 | +163.21% | $14.2B | SEC |
| Q3 2023 | Oct 31, 2023 | −$0.08 | −$0.17 | −113.03% | $13.2B | SEC |
| Q2 2023 | Aug 1, 2023 | $0.57 | $0.67 | +17.52% | $12.7B | SEC |
| Q1 2023 | May 2, 2023 | $0.98 | $1.23 | +24.97% | $18.3B | SEC |
| Q4 2022 | Jan 31, 2023 | $1.05 | $1.14 | +8.91% | $24.3B | SEC |
| Q3 2022 | Nov 1, 2022 | $1.39 | $1.78 | +28.30% | $22.6B | SEC |
| Q2 2022 | Jul 28, 2022 | $1.72 | $2.04 | +18.30% | $27.7B | SEC |
| Q1 2022 | May 3, 2022 | $1.49 | $1.62 | +8.48% | $25.7B | SEC |
| Q4 2021 | Feb 8, 2022 | $0.87 | $1.08 | +23.54% | $23.8B | SEC |
| Q3 2021 | Nov 2, 2021 | $1.08 | $1.34 | +24.43% | $24.1B | SEC |
Quarterly revenue
Frequently asked questions
When did Pfizer (PFE) last report earnings?
Pfizer last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did PFE beat earnings estimates?
Yes. Pfizer reported EPS of $0.77 for Q2 2026 against a $0.68 estimate — a 12.87% beat.
How much revenue did PFE report last quarter?
Pfizer reported $15.0B in revenue for Q2 2026, against a consensus estimate of $14.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.